emerg
novel
coronaviru
name
sever
acut
respiratori
syndrom
coronaviru
formerli
initi
global
effort
identifi
effect
treatment
focus
agent
demonstr
antivir
activ
middl
east
respiratori
syndrom
relat
positivesens
rna
virus
although
current
approv
antivir
drug
treatment
human
coronaviru
infect
avail
preclin
data
nucleotid
analog
remdesivir
rdv
promis
human
safeti
data
avail
compound
show
broad
spectrum
antivir
activ
sever
rna
virus
includ
rdv
origin
develop
treatment
ebola
viru
diseas
cellcultur
anim
studi
reveal
potent
antivir
activ
filovirus
includ
ebola
viru
ebov
subsequ
studi
shown
rdv
also
activ
coronavirus
diverg
rnadepend
rna
polymeras
rdrp
howev
biochem
data
support
find
provid
possibl
mechan
action
avail
triphosph
form
rdv
rdvtp
shown
inhibit
rdrp
respiratori
syncyti
viru
nipah
viru
ebov
nonseg
negativesens
rna
virus
activ
ebola
rdrp
contain
viral
l
protein
complex
viral
protein
viral
protein
function
counterpart
p
protein
respiratori
syncyti
viru
nipah
previous
gener
recombin
ebola
rdrp
studi
nucleotid
analog
inhibitor
enzym
kinet
show
rdvtp
abl
compet
natur
counterpart
atp
incorpor
select
atp
inhibitor
incorpor
posit
compound
caus
inhibit
rna
synthesi
predominantli
posit
delay
chain
termin
therefor
plausibl
mechan
action
progress
also
made
character
rdrp
complex
biochem
data
suggest
activ
complex
compos
least
three
viral
nonstructur
protein
rna
polymeras
alon
display
low
process
synthesi
longer
reaction
product
requir
addit
presenc
although
heterotrim
stabl
link
togeth
form
complex
develop
novel
express
system
rdrp
complex
studi
mechan
action
remdesivir
coexpress
mer
proteas
insect
cell
yield
stabl
complex
compos
demonstr
complex
activ
model
primertempl
substrat
adequ
mimic
elong
state
importantli
select
measur
determin
inher
limit
steadyst
condit
reveal
incorpor
inhibitor
effici
natur
counterpart
delay
chain
termin
observ
posit
baculoviru
express
system
recent
use
produc
recombin
activ
rdrp
complex
reconstitut
purifi
without
linker
express
escherichia
coli
employ
altern
approach
wherebi
mer
coexpress
insect
cell
part
polyprotein
ncbi
access
polyprotein
posttransl
cleav
proteas
origin
cleavag
site
fig
also
express
rdrp
complex
catalyt
residu
within
conserv
motif
c
sdd
mutat
snn
gener
inact
rdrp
fig
acid
affin
chromatographi
via
ntermin
eighthistidin
tag
protein
result
rdrp
complex
contain
kda
kda
fig
mass
spectroscopi
confirm
presenc
wherea
evid
presenc
wt
rdrp
complex
test
rna
synthesi
short
model
primertempl
substrat
mimick
random
elong
complex
rna
synthesi
recent
use
model
substrat
studi
rdrp
enzym
fig
templat
design
gtp
first
incorpor
nucleotid
label
rna
product
reaction
contain
rdrp
complex
primertempl
variou
combin
ntp
initi
addit
ion
presenc
gtp
alon
expect
product
form
addit
specif
combin
ntp
gener
defin
reaction
product
gtp
atp
yield
fig
left
side
gel
product
fig
right
side
gel
depend
templat
sequenc
similarli
presenc
gtp
atp
ctp
utp
primer
extend
yield
depend
templat
sequenc
addit
four
ntp
result
fulllength
product
reaction
snn
mutant
enzym
show
rna
product
format
lane
mark
gtp
illustr
background
signal
associ
gtp
prepar
absenc
enzym
data
confirm
exhibit
observ
rdrp
activ
recent
report
display
rna
primas
activ
yield
short
reaction
product
howev
structur
data
inconsist
format
primas
activ
site
data
provid
evid
primas
activ
ebov
rdrp
challeng
identifi
sequenc
singl
site
incorpor
rdv
henc
devis
two
differ
rna
templat
allow
multipl
singl
incorpor
respect
shown
fig
sequenc
use
compar
inhibitori
effect
rdv
ebov
rdrp
mer
rdrp
ebov
rdrp
observ
delay
chain
termin
posit
previous
describ
fig
howev
templat
provid
singl
site
rdvtp
incorpor
also
show
reduct
fulllength
rna
synthesi
contrast
mer
rdrp
complex
yield
fulllength
rna
product
sequenc
inhibit
pattern
rdvtp
differ
markedli
result
ebov
rdrp
rna
synthesi
arrest
posit
templat
provid
multipl
site
incorpor
inhibitor
fulllength
product
seen
faint
band
templat
allow
singl
incorpor
event
yield
rna
synthesi
arrest
posit
increas
amount
fulllength
product
henc
mechan
inhibit
like
delay
chain
termin
ebov
rdrp
mer
rdrp
although
specif
pattern
show
subtl
differ
absenc
inhibitor
rna
synthesi
fulllength
product
format
gener
effici
rdrp
could
also
help
explain
small
amount
fulllength
product
still
seen
enzym
presenc
inhibitor
studi
whether
rdvtp
abl
compet
natur
counterpart
atp
monitor
rna
synthesi
fix
concentr
ntp
increas
concentr
rdvtp
fig
top
panel
increas
concentr
rdvtp
caus
reduct
product
caus
increas
rna
synthesi
arrest
posit
format
fulllength
product
evid
rdvtp
concentr
higher
quantif
data
reveal
rdvtp
condit
fig
valu
higher
atp
concentr
point
effici
use
inhibitor
increas
concentr
atp
caus
correspond
increas
valu
rdvtp
fig
show
rdvtp
competit
inhibitor
translat
previou
find
quantit
term
determin
paramet
vmax
km
calcul
effici
vmaxkm
nucleotid
incorpor
atp
rdvtp
two
nucleotid
analog
inhibitor
compar
purpos
araatp
fig
atp
atp
analog
ad
increas
concentr
reaction
stop
min
follow
addit
approach
allow
us
determin
select
nucleotid
incorpor
defin
vmaxkm
atp
vmaxkm
nucleotid
analog
tabl
observ
differ
effici
nucleotid
analog
substrat
util
driven
sole
differ
respect
km
valu
data
show
unexpectedli
low
select
valu
rdvtp
wherea
araatp
associ
high
select
valu
select
valu
rdvtp
suggest
incorpor
inhibitor
effici
compar
natur
substrat
commonli
nucleotid
analog
less
effici
incorpor
seen
araatp
broad
spectrum
antivir
compound
demonstr
activ
consid
treatment
infect
caus
novel
coronaviru
nucleotid
analog
rdv
test
random
control
trial
ebola
viru
diseas
although
two
investig
therapi
efficaci
rdv
antivir
effect
demonstr
compound
also
show
broad
spectrum
antivir
activ
coronavirus
vitro
anim
model
moreov
screen
compound
librari
food
drug
drug
reveal
hiv
type
proteas
inhibitor
lopinavir
activ
drug
current
test
clinic
trial
treatment
combin
ritonavir
use
pharmacolog
boost
recent
studi
compar
efficaci
combin
rdv
cell
cultur
show
rdv
significantli
activ
focus
biochem
evalu
rdv
provid
better
understand
broad
spectrum
antivir
activ
underli
mechan
action
vitro
select
experi
coronaviru
model
murin
hepat
viru
result
two
variant
resistanceconf
mutat
data
provid
strong
evid
show
rdrp
target
rdv
biochem
data
corrobor
rna
polymeras
inde
drug
target
demonstr
mer
form
activ
binari
complex
rdvtp
util
substrat
compet
natur
counterpart
atp
natur
nucleotid
pool
commonli
effici
incorpor
compar
nucleotid
analog
howev
case
observ
incorpor
nucleotid
analog
significantli
effici
ad
grow
rna
chain
inhibitor
caus
immedi
chain
termin
presenc
group
allow
addit
three
nucleotid
rna
synthesi
arrest
posit
fraction
extend
primer
overcom
arrest
lead
fulllength
product
format
fulllength
product
format
consider
reduc
inhibitor
ad
consecut
site
effici
rate
rdvtp
incorpor
may
translat
multipl
incorpor
event
vivo
could
add
overal
potenc
drug
import
note
paramet
includ
intracellular
concentr
triphosph
form
inhibitor
need
consid
well
differ
inhibit
pattern
observ
ebov
rdrp
rdrp
point
subtl
differ
mechan
action
delay
chain
termin
could
base
inhibitorinduc
structur
chang
newli
synthes
dsrna
point
prevent
product
align
primer
incom
nucleotid
eg
primertempl
reposit
backtrack
mechan
enzymespecif
interact
extend
primer
may
likewis
affect
continu
extens
primer
help
explain
variat
site
rna
synthesi
arrest
open
question
warrant
investig
role
exonucleas
suscept
rdv
previous
report
nucleotid
analog
inhibitor
excis
viral
exonucleas
murin
hepat
viru
mutant
lack
exonucleas
activ
shown
sensit
rdv
howev
given
high
potenc
cellbas
assay
rdv
seem
protect
excis
least
certain
degre
protect
could
provid
addit
three
nucleotid
follow
inhibitor
contrast
classic
chain
termin
would
readili
access
excis
taken
togeth
studi
provid
like
mechan
action
rdv
coronavirus
novel
strategi
express
rdrp
help
guid
design
equival
construct
relat
virus
includ
rna
primer
templat
use
studi
purchas
dharmacon
lafayett
co
rdvtp
gilead
scienc
foster
citi
ca
araatp
purchas
trilink
san
diego
ca
ntp
purchas
ge
healthcar
gtp
purchas
perkinelm
invitrogen
plasmid
codonoptim
synthet
dna
sequenc
genscript
piscataway
nj
code
portion
polyprotein
ncbi
access
contain
use
start
materi
protein
express
insect
cell
invitrogen
employ
multibac
geneva
biotech
indianapoli
system
protein
express
insect
cell
invitrogen
accord
publish
protocol
protein
complex
purifi
use
acid
affin
chromatographi
ntermin
eighthistidin
tag
accord
manufactur
specif
thermo
scientif
ident
purifi
protein
confirm
ms
analysi
dr
jack
moor
alberta
proteom
mass
spectrometri
edmonton
canada
express
purif
ebov
rdrp
complex
perform
previous
describ
data
acquisit
quantif
done
previous
report
us
rna
synthesi
assay
consist
mix
final
concentr
trishcl
ph
mm
rna
primer
rna
templat
ntp
variou
concentr
combin
indic
ntp
ntp
analog
rdrp
complex
ice
reaction
mixtur
incub
min
follow
addit
mm
reaction
stop
min
addit
formamideedta
mm
mixtur
incub
min
reaction
sampl
subject
denatur
urea
page
resolv
product
rna
synthesi
follow
signal
quantif
imagequ
ge
healthcar
bioscienc
phosphorimag
typhoon
trio
variabl
mode
imag
ge
healthcar
bioscienc
nucleotid
incorpor
experi
atp
atp
analog
inhibitor
ad
increas
concentr
reaction
stop
fix
time
point
min
follow
addit
reaction
condit
chosen
format
product
ie
primer
extend
gtp
linear
respect
time
time
point
product
fraction
determin
total
signal
band
plot
versu
atp
atp
analog
substrat
concentr
fit
equat
use
graphpad
prism
graphpad
softwar
inc
san
diego
ca
vmax
km
paramet
assay
involv
incorpor
gtp
primer
approach
possibl
quantifi
fraction
extend
primer
howev
reaction
product
clearli
defin
correct
incorpor
gtp
potenti
confound
byproduct
caus
misalign
primer
invis
case
experi
full
templatelength
product
fraction
plot
versu
rdvtp
concentr
fit
log
inhibitor
respons
variabl
slope
equat
use
graphpad
prism
determin
valu
inhibit
rna
synthesi
rdvtp
concentr
nucleotid
substrat
competit
assay
chosen
around
km
valu
atp
tabl
c
j
g
e
p
g
formal
analysi
c
j
g
e
p
g
investig
c
j
g
e
p
g
methodolog
e
p
g
data
curat
e
p
softwar
e
p
g
valid
e
p
g
visual
e
p
j
f
dpp
g
writingreview
edit
g
conceptu
g
resourc
g
supervis
g
fund
acquisit
g
writingorigin
draft
g
project
administr
